– Data presented at EASD, Barcelona demonstrate the ability of ZP3022, a dual-acting GLP-1-gastrin agonist to significantly increase beta cell proliferation, reduce apoptosis and enhance glucose-stimulated insulin secretion in preclinical in-vitro models
– These new results further highlight Zealand’s unique capabilities in peptide drug innovation and design
COPENHAGEN, Denmark I September 26, 2013 I Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that new preclinical data on ZP3022, a novel peptide receptor agonist from the company’s GLP-1-gastrin dual agonist program, is presented during a poster session today entitled “Effects of a novel GLP-1-gastrin dual agonist, ZP3022, on beta cell proliferation, apoptosis and functional capacity” at the 49th European Association for the Study of Diabetes (EASD) in Barcelona, Spain.
Data presented earlier have shown that treatment with the GLP-1-gastrin dual agonist ZP3022 improves the glycemic control and glucose tolerance in preclinical models of type 2 diabetes (db/db mice and Zucker Diabetic Fatty (ZDF) rats). These results were accompanied by a significant increase in beta cell mass, which was also significant compared to liraglutide. The studies presented at EASD today investigated the in-vitro effects of ZP3022 on the regulation of pancreatic beta cell proliferation, on pancreatic islets cell survival and on the functional capacity of beta cells in isolated rat islets of Langerhans. The study findings demonstrate that this GLP-1-gastrin dual agonist significantly increases beta cell proliferation, reduces apoptosis and enhances glucose-stimulated insulin secretion.
The poster is available as an ePoster on the EASD website and on Zealand’s website: www.zealandpharma.com.
Commenting on the findings, David Solomon, President and Chief Executive Officer of Zealand Pharma, said: “We are highly encouraged by the new data we are presenting on ZP3022, and we look forward to further explore the valuable potential for this unique Zealand peptide drug candidate as a novel approach for the treatment and prevention of type 2 diabetes. This compound is an example of Zealand’s leading capabilities in the field of peptide drug innovation and design, and the GLP-1-gastrin dual agonist program is one of the many promising projects within our preclinical pipeline.
About Zealand
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead drug invention is lixisenatide, a once-daily prandial GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide (marketed by Sanofi as Lyxumia®) is approved in Europe and Japan and under regulatory review in a number of other countries globally. In the U.S., an NDA is planned to be submitted in 2015, after completion of the ELIXA CV outcome study.
Zealand has a partnering strategy for the development and commercialization of its products and in addition to the license agreement with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.
SOURCE: Zealand Pharma
Post Views: 349
– Data presented at EASD, Barcelona demonstrate the ability of ZP3022, a dual-acting GLP-1-gastrin agonist to significantly increase beta cell proliferation, reduce apoptosis and enhance glucose-stimulated insulin secretion in preclinical in-vitro models
– These new results further highlight Zealand’s unique capabilities in peptide drug innovation and design
COPENHAGEN, Denmark I September 26, 2013 I Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that new preclinical data on ZP3022, a novel peptide receptor agonist from the company’s GLP-1-gastrin dual agonist program, is presented during a poster session today entitled “Effects of a novel GLP-1-gastrin dual agonist, ZP3022, on beta cell proliferation, apoptosis and functional capacity” at the 49th European Association for the Study of Diabetes (EASD) in Barcelona, Spain.
Data presented earlier have shown that treatment with the GLP-1-gastrin dual agonist ZP3022 improves the glycemic control and glucose tolerance in preclinical models of type 2 diabetes (db/db mice and Zucker Diabetic Fatty (ZDF) rats). These results were accompanied by a significant increase in beta cell mass, which was also significant compared to liraglutide. The studies presented at EASD today investigated the in-vitro effects of ZP3022 on the regulation of pancreatic beta cell proliferation, on pancreatic islets cell survival and on the functional capacity of beta cells in isolated rat islets of Langerhans. The study findings demonstrate that this GLP-1-gastrin dual agonist significantly increases beta cell proliferation, reduces apoptosis and enhances glucose-stimulated insulin secretion.
The poster is available as an ePoster on the EASD website and on Zealand’s website: www.zealandpharma.com.
Commenting on the findings, David Solomon, President and Chief Executive Officer of Zealand Pharma, said: “We are highly encouraged by the new data we are presenting on ZP3022, and we look forward to further explore the valuable potential for this unique Zealand peptide drug candidate as a novel approach for the treatment and prevention of type 2 diabetes. This compound is an example of Zealand’s leading capabilities in the field of peptide drug innovation and design, and the GLP-1-gastrin dual agonist program is one of the many promising projects within our preclinical pipeline.
About Zealand
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead drug invention is lixisenatide, a once-daily prandial GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide (marketed by Sanofi as Lyxumia®) is approved in Europe and Japan and under regulatory review in a number of other countries globally. In the U.S., an NDA is planned to be submitted in 2015, after completion of the ELIXA CV outcome study.
Zealand has a partnering strategy for the development and commercialization of its products and in addition to the license agreement with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.
SOURCE: Zealand Pharma
Post Views: 349
